Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Sagent Pharmaceuticals

Related SGNT
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
ETFs For The Next Pharma Takeover Candidates

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Sagent Pharmaceuticals (NASDAQ: SGNT).

Morgan Stanley noted, “Total November IMS sales were $17MM establishing a 4Q12 run rate of $53MM in-line with MSe and Cns of $52MM and guidance of ~$50MM. However, the focus is now on 2013 commercial momentum and we are comfortable with our $227MM estimate for 2013 (consensus of $243MM) driven by new launches and firming base business performance.”

Sagent Pharmaceuticals closed on Friday at $15.70.

Latest Ratings for SGNT

Aug 2015RBC CapitalUpgradesSector PerformOutperform
Jun 2015Raymond JamesInitiates Coverage onStrong Buy
Apr 2015Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (SGNT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters